Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients

The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is known to play an important role in antiapoptotic signaling and has been implicated in the aggressiveness of a number of different human cancers including acute myeloid leukemia (AML). The progression of myelodysplastic syndromes (MDSs) to AML is thought to be associated with abrogation of apoptotic control mechanisms. However, little is known about signal transduction pathways which may be involved in enhanced survival of MDS cells. In this report, we have performed immunocytochemical and flow cytometric analysis to evaluate the levels of activated Akt in bone marrow or peripheral blood mononuclear cells from patients diagnosed with MDS. We observed high levels of Ser473 phosphorylated Akt (p-Akt) staining in 90% of the cases (n=22) diagnosed as high-risk MDS, whereas mononuclear cells from normal bone marrow or low-risk MDS patients showed low or absent Ser473 p-Akt staining. Furthermore, all high-risk MDS patients also demonstrated high expression of the Class I PI3K p110δ catalytic subunit and a decreased expression of PTEN. Taken together, our results suggest that Akt activation might be one of the factors contributing to the decreased apoptosis rate observed in patients with high-risk MDS.

[1]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[2]  R. Davis,et al.  Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. , 1998, Leukemia research.

[3]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[4]  John Calvin Reed,et al.  The AKT kinase is activated in multiple myeloma tumor cells. , 2001, Blood.

[5]  T. Hunter,et al.  Receptor protein-tyrosine kinases and their signal transduction pathways. , 1994, Annual review of cell biology.

[6]  K. Kishi,et al.  Simultaneous expression of CD13, CD22 and CD25 is related to the expression of FcεR1 in non-lymphoid leukemia , 2004 .

[7]  A. Ruggeri,et al.  A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells , 2003, Leukemia.

[8]  K. Kishi,et al.  Simultaneous expression of CD13, CD22 and CD25 is related to the expression of Fc epsilon R1 in non-lymphoid leukemia. , 2004, Leukemia research.

[9]  J. Woodgett.  Recent advances in the protein kinase B signaling pathway. , 2005, Current opinion in cell biology.

[10]  M. Zvelebil,et al.  p110δ, a novel phosphoinositide 3-kinase in leukocytes , 1997 .

[11]  M Zweyer,et al.  The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27Kip1 and control of cyclin D1 expression , 2003, Leukemia.

[12]  A. Martelli,et al.  Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation , 2003, Leukemia.

[13]  E. Solary,et al.  Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. , 2005, Blood.

[14]  G. Mufti,et al.  The Myelodysplastic Syndromes: A Matter of Life or Death , 2003, Acta Haematologica.

[15]  P. Kiener,et al.  A role for tumour necrosis factor‐α, Fas and Fas‐Ligand in marrow failure associated with myelodysplastic syndrome , 1998, British journal of haematology.

[16]  M. Zvelebil,et al.  a novel phosphoinositide 3-kinase in leukocytes , 1997 .

[17]  G. Martinelli,et al.  Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry , 2004, British journal of haematology.

[18]  A. Khwaja,et al.  PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways , 2005, Leukemia.

[19]  H. Wu,et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Toker,et al.  Signalling through the lipid products of phosphoinositide-3-OH kinase , 1997, Nature.

[21]  P. Greenberg,et al.  Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. , 1998, Leukemia research.

[22]  G. Mufti,et al.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.

[23]  L. Shih,et al.  Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia , 2004, Leukemia.

[24]  E. Vellenga,et al.  Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway , 2004, Leukemia.

[25]  E. Solary,et al.  Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .

[26]  H. Deeg,et al.  High IGFBP-3 levels in marrow plasma in early-stage MDS: effects on apoptosis and hemopoiesis , 2005, Leukemia.

[27]  A. Hagemeijer,et al.  Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes , 2004, Leukemia.

[28]  Kenneth M. Yamada,et al.  Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. , 2001, Journal of cell science.

[29]  F. Tsai,et al.  Aberrant transcripts of FHIT, TSG101 and PTEN/MMAC1 genes in normal peripheral mononuclear cells. , 2000, International Journal of Oncology.

[30]  F. E. Bertrand,et al.  The complexity of PTEN: mutation, marker and potential target for therapeutic intervention , 2004, Expert opinion on therapeutic targets.

[31]  S. Gore.  Inhibitors of signaling in myelodysplastic syndrome. , 2004, Best practice & research. Clinical haematology.

[32]  J. D. Vos,et al.  Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes , 1997, Leukemia.

[33]  R. Steinman,et al.  Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Hemmings,et al.  Advances in protein kinase B signalling: AKTion on multiple fronts. , 2004, Trends in biochemical sciences.

[35]  M. Carroll,et al.  Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.

[36]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[37]  E. Vellenga,et al.  Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia. , 2003, Blood.

[38]  S. Fesik,et al.  Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL , 1997, Molecular and cellular biology.

[39]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[40]  O. Majdic,et al.  Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. , 1994, Cytometry.

[41]  David R. Kaplan,et al.  Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate , 1997, Science.

[42]  J. Cheong,et al.  Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable , 2003, Leukemia.

[43]  F. Lo‐Coco,et al.  Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells , 2005, Leukemia.

[44]  A. Weiss,et al.  The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[45]  T. Goldmann,et al.  Phosphoinositide 3-OH kinase inhibition prevents ventilation-induced lung cell activation. , 2004, American journal of respiratory and critical care medicine.

[46]  Angel F. Lopez,et al.  The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2. , 2004, Blood.

[47]  R. Kurzrock,et al.  Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. , 2003, Blood.

[48]  F. E. Bertrand,et al.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.

[49]  F. Prósper,et al.  Nuclear factor k B is activated in myelodysplastic bone marrow cells. , 2002, Haematologica.

[50]  G. Mills,et al.  Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias , 2004, Leukemia.

[51]  J. Bennett,et al.  Understanding the Myelodysplastic Syndromes. , 1997, The oncologist.